Sermorelin and CJC-1295 + Ipamorelin Together: What Is Known
Sermorelin and CJC-1295 + Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 4 results, 2 Oct 2026).
Side by side
Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | Sermorelin | CJC-1295 + Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRH + GHRP blend |
| Also called | — | CJC/Ipa |
| Category | Growth hormone | Growth hormone |
| FDA status | Compounded by prescription | Not FDA approved · research blend |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. | Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 | Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030 |
| Human studies we summarised | 6 human (1 randomized or controlled) of 9 summarised | 6 human (3 randomized or controlled) of 19 summarised, across ingredients |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 9 mg, 15 mg | 10 mg |
Sermorelin vs CJC-1295 + Ipamorelin
Choosing between the two rather than combining them? The comparison lines them up field by field.
The closest human data pairs sermorelin with other peptides
The closest human study is a chart review of men on testosterone given GHRP/sermorelin combination therapy: mean continuous treatment lasted 134 days and mean posttreatment IGF-1 was 239.0 ng/mL.[5]
Its authors suggest the combination may be beneficial in men with wasting conditions that can improve with increased GH secretion. That is their suggestion, not a measured outcome.[5]
In healthy older men, sermorelin-type GHRH given nightly raised nocturnal GH release.[6]
What is known about the blend
CJC-1295's human studies are in healthy adults and measure GH and IGF-I.[13]
Ipamorelin's randomised trial found no significant difference from placebo in its key and secondary efficacy analyses.[12]
A PubMed search on 2 Oct 2026 for CJC-1295 plus ipamorelin together with sermorelin matched 4 records; none is recorded as a trial of the combination.
Calculated from pubmed query (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab]); records matched 4; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
Regulatory and sport status
Sermorelin's sole FDA entries are discontinued Geref records.[18]
FDA reports serious adverse events for CJC-1295, including increased heart rate and vasodilatory reaction.[19]
WADA's list names sermorelin and CJC-1295 together as GHRH analogues.[1]
Common questions
Sermorelin vs CJC-1295 ipamorelin: which is better?
No trial compares them. Sermorelin has paediatric trials and a discontinued brand; the blend has human data only for its separate components.[15]
Can sermorelin be stacked with CJC-1295 and ipamorelin?
No study has tested that combination. The nearest report combined sermorelin with GHRP-6 and GHRP-2 in men on testosterone.[5]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 13Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 14PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 16Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 17PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 19Official web pageOfficial web page · web page
Found an error? Report a correction.